CH371454A - Verfahren zur Herstellung von Sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyden - Google Patents

Verfahren zur Herstellung von Sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyden

Info

Publication number
CH371454A
CH371454A CH6978359A CH6978359A CH371454A CH 371454 A CH371454 A CH 371454A CH 6978359 A CH6978359 A CH 6978359A CH 6978359 A CH6978359 A CH 6978359A CH 371454 A CH371454 A CH 371454A
Authority
CH
Switzerland
Prior art keywords
dioxydes
benzothiadiazine
sulfamyl
dihydro
preparation
Prior art date
Application number
CH6978359A
Other languages
English (en)
Inventor
Destevens George
Harvey Werner Lincoln
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Priority to CH1856359A priority Critical patent/CH387643A/de
Priority to CH1826359A priority patent/CH380147A/de
Priority to CH1836359A priority patent/CH380148A/de
Publication of CH371454A publication Critical patent/CH371454A/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
    • C07D285/28—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
    • C07D285/30—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with hydrocarbon radicals, substituted by hetero atoms, attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CH6978359A 1958-03-03 1959-02-19 Verfahren zur Herstellung von Sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyden CH371454A (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CH1856359A CH387643A (de) 1958-03-03 1959-02-19 Verfahren zur Herstellung von Sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
CH1826359A CH380147A (de) 1958-03-03 1959-02-19 Verfahren zur Herstellung von Sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
CH1836359A CH380148A (de) 1958-03-03 1959-02-19 Verfahren zur Herstellung von Sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyden

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US71845258A 1958-03-03 1958-03-03
US72724258A 1958-04-09 1958-04-09
US74058258A 1958-06-09 1958-06-09
US75162058A 1958-07-29 1958-07-29
US76448258A 1958-09-29 1958-09-29
DEC0024178 1959-02-27
DEC0028408 1959-02-27
DEC0028409 1959-02-27
DEC0024177 1959-02-27
DEC0024176 1959-02-27

Publications (1)

Publication Number Publication Date
CH371454A true CH371454A (de) 1963-08-31

Family

ID=27579177

Family Applications (4)

Application Number Title Priority Date Filing Date
CH6978359A CH371454A (de) 1958-03-03 1959-02-19 Verfahren zur Herstellung von Sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
CH18463A CH387642A (de) 1958-03-03 1959-02-19 Verfahren zur Herstellung von Sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
CH18163A CH377365A (de) 1958-03-03 1959-02-19 Verfahren zur Herstellung von Sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
CH18063A CH376514A (de) 1958-03-03 1959-02-19 Verfahren zur Herstellung von Sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyden

Family Applications After (3)

Application Number Title Priority Date Filing Date
CH18463A CH387642A (de) 1958-03-03 1959-02-19 Verfahren zur Herstellung von Sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
CH18163A CH377365A (de) 1958-03-03 1959-02-19 Verfahren zur Herstellung von Sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
CH18063A CH376514A (de) 1958-03-03 1959-02-19 Verfahren zur Herstellung von Sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyden

Country Status (6)

Country Link
CH (4) CH371454A (de)
DE (4) DE1445005A1 (de)
FR (2) FR1217929A (de)
GB (1) GB861367A (de)
MY (1) MY6200051A (de)
OA (2) OA01178A (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3200117A (en) * 1962-10-03 1965-08-10 Hoffmann La Roche Derivatives of 1, 2, 4-benzothiadiazine-7-sulfonamide-1, 1-dioxide
DE2642140C2 (de) * 1976-09-20 1982-10-28 Degussa Ag, 6000 Frankfurt Verfahren zur Herstellung von Benzoylcyanid
DE8700284U1 (de) * 1987-01-07 1987-04-30 Ernst Reiner GmbH & Co KG, 7743 Furtwangen Post-Datumstempel
CA2320354A1 (en) * 1998-02-18 1999-08-26 Neurosearch A/S Novel compounds and their use as positive ampa receptor modulators
US6943159B1 (en) 1998-02-18 2005-09-13 Neurosearch A/S Compounds and their use as positive AMPA receptor modulators
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
PT1355644E (pt) 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
EP1429756B1 (de) 2001-09-21 2006-11-22 Schering Corporation Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
EP1545519B1 (de) 2002-08-19 2011-03-23 Pfizer Inc. Kombinationstherapie gegen hyperproliferative erkrankungen
JP2006508188A (ja) 2002-11-06 2006-03-09 シェーリング　コーポレイション 脱髄の処置のためのコレステロール吸収インヒビター
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
EP2810951B1 (de) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof

Also Published As

Publication number Publication date
DE1112079B (de) 1961-08-03
MY6200051A (en) 1962-12-31
CH376514A (de) 1964-04-15
DE1445005A1 (de) 1968-10-24
OA01178A (fr) 1969-01-25
FR1217929A (fr) 1960-05-06
DE1445007A1 (de) 1968-10-24
OA03826A (fr) 1971-12-24
CH387642A (de) 1965-02-15
FR1264468A (fr) 1961-06-23
DE1445006B2 (de) 1975-05-07
DE1445574A1 (de) 1969-01-16
DE1445008A1 (de) 1968-10-24
GB861367A (en) 1961-02-22
DE1445006A1 (de) 1968-10-24
CH377365A (de) 1964-05-15

Similar Documents

Publication Publication Date Title
CH381696A (de) Verfahren zur Herstellung von 1,3,4-Oxadiazolen
CH444167A (de) Verfahren zur Herstellung von 6-Trifluormethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyd
CH379488A (de) Verfahren zur Herstellung von 1,4-Dicyanbutenen
CH392526A (de) Verfahren zur Herstellung von 3,4-Dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
CH389627A (de) Verfahren zur Herstellung von 3,4-Dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
CH396919A (de) Verfahren zur Herstellung von neuen Derivaten des 7-Sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyds
CH383391A (de) Verfahren zur Herstellung von 1,2,4-Benzothiadiazin-1,1-dioxyden
AT254877B (de) Verfahren zur Herstellung von 7-Sulfonamido-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
CH396015A (de) Verfahren zur Herstellung von 3,4-Dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
CH389628A (de) Verfahren zur Herstellung von 2,4-Diamino-chinazolinen
CH380148A (de) Verfahren zur Herstellung von Sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
CH385218A (de) Verfahren zur Herstellung von 3-substituierten 6-Trifluormethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
CH405331A (de) Verfahren zur Herstellung von 3,4-Dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
CH381240A (de) Verfahren zur Herstellung von 3,4-Dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
AT216513B (de) Verfahren zur Herstellung von neuen 3,4-Dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
AT209341B (de) Verfahren zur Herstellung von 1,3,4-Oxdiazolen
CH403781A (de) Verfahren zur Herstellung von 3,4-Dihydro-1,2,4-benzothiadiazin-1,1-dioxyd-7-sulfonsäureamiden
CH387648A (de) Verfahren zur Herstellung von 1,9- oder 1,10-Diaminooctadecan
AT234694B (de) Verfahren zur Herstellung von neuen 3,3-disubstituierten 7-Sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
AT216515B (de) Verfahren zur Herstellung von neuen 3,4-Dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
AT227702B (de) Verfahren zur Herstellung von neuen 3,4-Dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
AT224641B (de) Verfahren zur Herstellung von neuen 3,4-Dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
AT216514B (de) Verfahren zur Herstellung von neuen 3,4-Dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
AT223201B (de) Verfahren zur Herstellung von neuen 3, 4-Dihydro-1, 2, 4-benzothiadiazin-1, 1-dioxyden
AT252257B (de) Verfahren zur Herstellung von 7-Sulfamyl-3,4-dihydro-1, 2, 4-benzothiadiazin-1, 1-dioxyden